Your browser doesn't support javascript.
loading
Acute myeloid leukemia patients' clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts.
Reis, Bernhard; Jukofsky, Lori; Chen, Gong; Martinelli, Giovanni; Zhong, Hua; So, W Venus; Dickinson, Michael J; Drummond, Mark; Assouline, Sarit; Hashemyan, Maneja; Theron, Michel; Blotner, Steven; Lee, Je-Hwan; Kasner, Margaret; Yoon, Sung-Soo; Rueger, Ruediger; Seiter, Karen; Middleton, Steven A; Kelly, Kevin R; Vey, Norbert; Yee, Karen; Nichols, Gwen; Chen, Lin-Chi; Pierceall, William E.
Afiliação
  • Reis B; Roche Innovation Center Basel, Roche Pharma Research and Early Development, Switzerland.
  • Jukofsky L; Roche Innovation Center New York, Roche Pharma Research and Early Development, NY, USA.
  • Chen G; Roche Innovation Center New York, Roche Pharma Research and Early Development, NY, USA.
  • Martinelli G; Seragnoli Institute of Hematology, Bologna University School of Medicine, Italy.
  • Zhong H; Roche Innovation Center New York, Roche Pharma Research and Early Development, NY, USA.
  • So WV; Roche Innovation Center New York, Roche Pharma Research and Early Development, NY, USA.
  • Dickinson MJ; Department of Haematology, Peter MacCallum Cancer Center, Melbourne, VIC, Australia.
  • Drummond M; Beatson West of Scotland Cancer Center, Gartnavel General Hospital, Glasgow, United Kingdom.
  • Assouline S; Division of Hematology, Jewish General Hospital, McGill University, Montreal, QC, Canada.
  • Hashemyan M; Roche Innovation Center New York, Roche Pharma Research and Early Development, NY, USA.
  • Theron M; Roche Innovation Center Basel, Roche Pharma Research and Early Development, Switzerland.
  • Blotner S; Roche Innovation Center New York, Roche Pharma Research and Early Development, NY, USA.
  • Lee JH; Department of Hematology, Asian Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
  • Kasner M; Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.
  • Yoon SS; Department of Internal Medicine, Seoul National University School of Medicine, Seoul, South Korea.
  • Rueger R; Roche Innovation Center Penzberg, Roche Pharma Research and Early Development, Germany.
  • Seiter K; New York Medical College, Valhalla, NY, USA.
  • Middleton SA; Roche Innovation Center New York, Roche Pharma Research and Early Development, NY, USA.
  • Kelly KR; University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
  • Vey N; Hematology, Institut Paoli Calmettes, Marseilles, France.
  • Yee K; Princess Margaret Hospital, Toronto, ON, Canada.
  • Nichols G; Roche Innovation Center New York, Roche Pharma Research and Early Development, NY, USA.
  • Chen LC; Roche Innovation Center New York, Roche Pharma Research and Early Development, NY, USA.
  • Pierceall WE; Roche Innovation Center New York, Roche Pharma Research and Early Development, NY, USA william.pierceall@roche.com.
Haematologica ; 101(5): e185-8, 2016 05.
Article em En | MEDLINE | ID: mdl-26869629
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirrolidinas / Leucemia Mieloide Aguda / Crise Blástica / Regulação Leucêmica da Expressão Gênica / Proteínas Proto-Oncogênicas c-mdm2 / Para-Aminobenzoatos Tipo de estudo: Risk_factors_studies Limite: Female / Humans / Male Idioma: En Ano de publicação: 2016 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirrolidinas / Leucemia Mieloide Aguda / Crise Blástica / Regulação Leucêmica da Expressão Gênica / Proteínas Proto-Oncogênicas c-mdm2 / Para-Aminobenzoatos Tipo de estudo: Risk_factors_studies Limite: Female / Humans / Male Idioma: En Ano de publicação: 2016 Tipo de documento: Article